Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics ...

Avidity Biosciences (NASDAQ:RNA) stock surged 18% Wednesday after the Financial Times reported that Swiss pharmaceutical ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech ...

There is no certainty that the buyout will come to pass, according to The Financial Times, which first reported the rumors.

If a deal is confirmed and consummated, Novartis would claim ownership of a biotech that has raised something of a stir in ...

Novartis has made a takeover approach for rare disease-focused biotech Avidity Biosciences, as Big Pharma continues to hunt ...

Swiss pharmaceutical giant Novartis is exploring a potential acquisition of U.S. biotech firm Avidity Biosciences, according ...

Del-zota is designed for patients with mutations amenable to exon 44 skipping, which is just 7% of the overall DMD patient population, Avidity believes, although the biotech states that it is "the ...

Avidity Biosciences stock has gained more than 20% in the past five days due to positive long-term data for its lead candidate, AOC 1001, in the MARINA-OLE trial in DM1 patients.

Shares of Avidity Biosciences Inc. soared 50% in their trading debut on the Nasdaq on Friday after pricing at the top of their initial public offering range, a sign of heightened interest from ...

Avidity Bioscienes (NASDAQ:RNA) quickly soared 20% after a report that Novartis (NYSE:NVS) made a takeover approach for the ...